NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS
🇬🇷Greece
Error parsing response
Error occurred while parsing the model response.
ASH 2024: Early Detection Strategies Show Promise in Multiple Myeloma
• A novel "Multiple Myeloma-like" (MM-like) score, based on genomic markers, accurately predicts progression risk in precursor conditions, potentially guiding early intervention.
• Mass spectrometry identifies M-proteins up to 22 years before MGUS or multiple myeloma diagnosis, revealing earliest disease stages for novel prevention strategies.
• PANGEA 2.0, a new tool, improves risk stratification for smoldering multiple myeloma patients, enhancing predictions compared to the current gold standard 20/2/20.
Cabazitaxel Shows Efficacy in Metastatic Castration-Resistant Prostate Cancer with Osseous Metastases
• A Phase II study (CabaBone) confirms cabazitaxel's efficacy in metastatic castration-resistant prostate cancer (mCRPC) patients, including those with HRR mutations, previously treated with docetaxel.
• The study found a 6-month progression-free survival rate of 47% and a 12-month overall survival rate of 70% in mCRPC patients with bone metastases treated with cabazitaxel.
• Reactive hematopoiesis in bone marrow biopsies was associated with improved survival, suggesting bone biomarkers could predict cabazitaxel efficacy in mCRPC patients.
• No new safety issues were detected, reinforcing cabazitaxel as a viable treatment option for mCRPC patients with osseous metastases.
Isatuximab Combinations Show Promise in Newly Diagnosed Multiple Myeloma
• Isatuximab plus VRd significantly reduced disease progression or death risk by 40.4% in transplant-ineligible newly diagnosed multiple myeloma patients.
• The FDA approved isatuximab-irfc with VRd for transplant-ineligible multiple myeloma, based on the IMROZ trial data.
• Isatuximab-RVd induction therapy improved progression-free survival in transplant-eligible newly diagnosed multiple myeloma patients, GMMG-HD7 trial showed.
• The addition of isatuximab to RVd led to higher rates of minimal residual disease negativity, indicating deeper responses.
ANGLE and Illumina's Dual DNA Analysis Improves Lung Cancer Biomarker Detection
• ANGLE plc and Illumina have successfully combined technologies for dual analysis of circulating tumor DNA (ctDNA) and circulating tumor cell DNA (CTC-DNA).
• In a study of 27 lung cancer patients, combined analysis identified twice as many mutations compared to ctDNA analysis alone, enhancing biomarker detection.
• The dual analysis workflow, utilizing Illumina's NGS platform, showed that CTC-DNA analysis could reveal mutations missed by ctDNA analysis, especially in treated patients.
• Illumina has highlighted ANGLE's findings at a European Association for Cancer Research webinar, indicating the importance of this combined approach.
Tenecteplase Shows Superior Stroke Recovery Outcomes Compared to Alteplase in Meta-Analysis
• A meta-analysis of 11 studies reveals that tenecteplase is associated with a higher likelihood of excellent recovery in ischemic stroke patients compared to alteplase.
• Tenecteplase-treated patients showed a 5% greater chance of excellent functional outcome and a 10% reduced risk of disability three months post-stroke.
• While both drugs demonstrate similar safety profiles and increase the chances of good recovery, tenecteplase presents a statistically significant advantage.
• The findings support the potential shift towards tenecteplase as the preferred thrombolytic agent for acute ischemic stroke within the 4.5-hour window.
Comparative Efficacy of Treatment Regimens for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
A network meta-analysis compared the efficacy of various treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma, highlighting daratumumab-containing therapies and VRd as the most effective in improving progression-free survival and overall survival.
© Copyright 2025. All Rights Reserved by MedPath